Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-κB pathway, independently of the fusion oncoprotein.

  • Hernández-Muñoz, Inmaculada
  • Figuerola, Elisabeth
  • Sánchez-Molina, Sara
  • Rodríguez García, Eva
  • Fernández Mariño, Ana Isabel, 1984-
  • Pardo-Pastor, Carlos
  • Bahamonde Santos, María Isabel, 1972-
  • Fernández-Fernández, José Manuel, 1967-
  • García-Domínguez, Daniel J.
  • Hontecillas-Prieto, Lourdes
  • Lavarino, Cinzia
  • Carcaboso, Angel M.
  • Torres, Carmen de
  • Tirado, Oscar M.
  • Alava, Enrique de
  • Mora, Jaume
Ewing sarcoma (ES) is an aggressive tumor defined by EWSR1 gene fusions that behave as an oncogene. Here we demonstrate that RING1B is highly expressed in primary ES tumors, and its expression is independent of the fusion oncogene. RING1B-depleted ES cells display an expression profile enriched in genes functionally involved in hematological development but RING1B depletion does not induce cellular differentiation. In ES cells, RING1B directly binds the SCN8A sodium channel promoter and its depletion results in enhanced Nav1.6 expression and function. The signaling pathway most significantly modulated by RING1B is NF-κB. RING1B depletion results in enhanced p105/p50 expression, which sensitizes ES cells to apoptosis by FGFR/SHP2/STAT3 blockade. Reduced NaV1.6 function protects ES cells from apoptotic cell death by maintaining low NF-κB levels. Our findings identify RING1B as a trait of the cell-of-origin and provide a potential targetable vulnerability., This work was supported by the Xarxa de Bancs de Tumors de Catalunya sponsored by Pla Director d’Oncologia de Catalunya and by grants from ISCIII-FEDER (PS09/00973; RIC RD12/0042/0014, Red HERACLES), Ministerio de Economía y Competitividad (MEC) (SAF2012-31089 and SAF2015-69762-R), FEDER Funds and by the Asociación Española Contra el Cáncer (AECC). E.Á.’s lab is supported by the AECC, MECFEDER (RD12/0036/0017, PT13/0010/0056, RTC-2014- 2102-1, ISCIII Sara Borrell CD06/00001, PI12/03102, PI14/01466), the European FP7 Projects EuroSARC (FP7- HEALTH-2011-two-stage, Project 278742 EUROSARC), Euroewing (FP7-HEALTH.2013.2.4.1-1, Project 602856), Fundación Memoria de DM Solorzano Barruso, Fundación Cris contra el Cáncer, Pablo Ugarte Foundation, and Fundación M. García Estrada. O.M.T. is funded by ISCIIIFEDER (CES12/021) and the AECC. AMC is funded by the European FP7 projects (FP7/2007-2013) under a Marie Curie International Reintegration Grant (PIRG- 08- GA-2010-276998) and ISCIII-FEDER (CP13/00189). The Ewing group at the Developmental Tumor Biology Laboratory, Hospital Sant Joan de Déu, is supported by the AECC and the generous donations from Pablo Ugarte Foundation.
Repisalud
Publicación Artículo científico (JournalArticle)

Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

  • Ferreira, Manuel A
  • Gamazon, Eric R
  • Al-Ejeh, Fares
  • Aittomäki, Kristiina
  • Andrulis, Irene L
  • Anton-Culver, Hoda
  • Arason, Adalgeir
  • Arndt, Volker
  • Aronson, Kristan J
  • Arun, Banu K
  • Asseryanis, Ella
  • Azzollini, Jacopo
  • Balmaña, Judith
  • Barnes, Daniel R
  • Barrowdale, Daniel
  • Beckmann, Matthias W
  • Behrens, Sabine
  • Benitez, Javier
  • Bermisheva, Marina
  • Białkowska, Katarzyna
  • Blomqvist, Carl
  • Bogdanova, Natalia V
  • Bojesen, Stig E
  • Bolla, Manjeet K
  • Borg, Ake
  • Brauch, Hiltrud
  • Brenner, Hermann
  • Broeks, Annegien
  • Burwinkel, Barbara
  • Caldés, Trinidad
  • Caligo, Maria A
  • Campa, Daniele
  • Campbell, Ian
  • Canzian, Federico
  • Carter, Jonathan
  • Carter, Brian D
  • Castelao, Jose E
  • Chang-Claude, Jenny
  • Chanock, Stephen J
  • Christiansen, Hans
  • Chung, Wendy K
  • Claes, Kathleen B M
  • Clarke, Christine L
  • Couch, Fergus J
  • Cox, Angela
  • Cross, Simon S
  • Czene, Kamila
  • Daly, Mary B
  • de la Hoya, Miguel
  • Dennis, Joe
  • Devilee, Peter
  • Diez, Orland
  • Dörk, Thilo
  • Dunning, Alison M
  • Dwek, Miriam
  • Eccles, Diana M
  • Ejlertsen, Bent
  • Ellberg, Carolina
  • Engel, Christoph
  • Eriksson, Mikael
  • Fasching, Peter A
  • Fletcher, Olivia
  • Flyger, Henrik
  • Friedman, Eitan
  • Frost, Debra
  • Gabrielson, Marike
  • Gago-Dominguez, Manuela
  • Ganz, Patricia A
  • Gapstur, Susan M
  • Garber, Judy
  • García-Closas, Montserrat
  • García-Sáenz, José A
  • Gaudet, Mia M
  • Giles, Graham G
  • Glendon, Gord
  • Godwin, Andrew K
  • Goldberg, Mark S
  • Goldgar, David E
  • González-Neira, Anna
  • Greene, Mark H
  • Gronwald, Jacek
  • Guénel, Pascal
  • Haiman, Christopher A
  • Hall, Per
  • Hamann, Ute
  • He, Wei
  • Heyworth, Jane
  • Hogervorst, Frans B L
  • Hollestelle, Antoinette
  • Hoover, Robert N
  • Hopper, John L
  • Hulick, Peter J
  • Humphreys, Keith
  • Imyanitov, Evgeny N
  • Isaacs, Claudine
  • Jakimovska, Milena
  • Jakubowska, Anna
  • James, Paul A
  • Janavicius, Ramunas
  • Jankowitz, Rachel C
  • John, Esther M
  • Johnson, Nichola
  • Joseph, Vijai
  • Karlan, Beth Y
  • Khusnutdinova, Elza
  • Kiiski, Johanna I
  • Ko, Yon-Dschun
  • Jones, Michael E
  • Konstantopoulou, Irene
  • Kristensen, Vessela N
  • Laitman, Yael
  • Lambrechts, Diether
  • Lazaro, Conxi
  • Leslie, Goska
  • Lester, Jenny
  • Lesueur, Fabienne
  • Lindström, Sara
  • Long, Jirong
  • Loud, Jennifer T
  • Lubiński, Jan
  • Makalic, Enes
  • Mannermaa, Arto
  • Manoochehri, Mehdi
  • Margolin, Sara
  • Maurer, Tabea
  • Mavroudis, Dimitrios
  • McGuffog, Lesley
  • Meindl, Alfons
  • Menon, Usha
  • Michailidou, Kyriaki
  • Miller, Austin
  • Montagna, Marco
  • Moreno, Fernando
  • Moserle, Lidia
  • Mulligan, Anna Marie
  • Nathanson, Katherine L
  • Neuhausen, Susan L
  • Nevanlinna, Heli
  • Nevelsteen, Ines
  • Nielsen, Finn C
  • Nikitina-Zake, Liene
  • Nussbaum, Robert L
  • Offit, Kenneth
  • Olah, Edith
  • Olopade, Olufunmilayo I
  • Olsson, Håkan
  • Osorio, Ana
  • Papp, Janos
  • Park-Simon, Tjoung-Won
  • Parsons, Michael T
  • Pedersen, Inge Sokilde
  • Peixoto, Ana
  • Peterlongo, Paolo
  • Pharoah, Paul D P
  • Plaseska-Karanfilska, Dijana
  • Poppe, Bruce
  • Presneau, Nadege
  • Radice, Paolo
  • Rantala, Johanna
  • Rennert, Gad
  • Risch, Harvey A
  • Saloustros, Emmanouil
  • Sanden, Kristin
  • Sawyer, Elinor J
  • Schmidt, Marjanka K
  • Schmutzler, Rita K
  • Sharma, Priyanka
  • Shu, Xiao-Ou
  • Simard, Jacques
  • Singer, Christian F
  • Soucy, Penny
  • Southey, Melissa C
  • Spinelli, John J
  • Spurdle, Amanda B
  • Stone, Jennifer
  • Swerdlow, Anthony J
  • Tapper, William J
  • Taylor, Jack A
  • Teixeira, Manuel R
  • Terry, Mary Beth
  • Teulé, Alex
  • Thomassen, Mads
  • Thöne, Kathrin
  • Thull, Darcy L
  • Tischkowitz, Marc
  • Toland, Amanda E
  • Torres, Diana
  • Truong, Thérèse
  • Tung, Nadine
  • Vachon, Celine M
  • van Asperen, Christi J
  • van den Ouweland, Ans M W
  • van Rensburg, Elizabeth J
  • Vega, Ana
  • Viel, Alessandra
  • Wang, Qin
  • Wappenschmidt, Barbara
  • Weitzel, Jeffrey N
  • Wendt, Camilla
  • Winqvist, Robert
  • Yang, Xiaohong R
  • Yannoukakos, Drakoulis
  • Ziogas, Argyrios
  • Kraft, Peter
  • Antoniou, Antonis C
  • Zheng, Wei
  • Easton, Douglas F
  • Milne, Roger L
  • Beesley, Jonathan
  • Chenevix-Trench, Georgia
Genome-wide association studies (GWAS) have identified more than 170 breast cancer susceptibility loci. Here we hypothesize that some risk-associated variants might act in non-breast tissues, specifically adipose tissue and immune cells from blood and spleen. Using expression quantitative trait loci (eQTL) reported in these tissues, we identify 26 previously unreported, likely target genes of overall breast cancer risk variants, and 17 for estrogen receptor (ER)-negative breast cancer, several with a known immune function. We determine the directional effect of gene expression on disease risk measured based on single and multiple eQTL. In addition, using a gene-based test of association that considers eQTL from multiple tissues, we identify seven (and four) regions with variants associated with overall (and ER-negative) breast cancer risk, which were not reported in previous GWAS. Further investigation of the function of the implicated genes in breast and immune cells may provide insights into the etiology of breast cancer.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

  • Lázaro García, Conxi
  • GC-HBOC Study Collaborators
  • GEMO Study Collaborators
  • EMBRACE Collaborators
  • HEBON Investigators
  • BCFR Investigators
  • ABCTB Investigators
Genome-wide association studies (GWAS) have identified more than 170 breast cancer susceptibility loci. Here we hypothesize that some risk-associated variants might act in non-breast tissues, specifically adipose tissue and immune cells from blood and spleen. Using expression quantitative trait loci (eQTL) reported in these tissues, we identify 26 previously unreported, likely target genes of overall breast cancer risk variants, and 17 for estrogen receptor (ER)-negative breast cancer, several with a known immune function. We determine the directional effect of gene expression on disease risk measured based on single and multiple eQTL. In addition, using a gene-based test of association that considers eQTL from multiple tissues, we identify seven (and four) regions with variants associated with overall (and ER-negative) breast cancer risk, which were not reported in previous GWAS. Further investigation of the function of the implicated genes in breast and immune cells may provide insights into the etiology of breast cancer.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24–25, 2015. Workshop Report

  • Kager, Leo
  • Whelan, Jeremy
  • Dirksen, Uta
  • Hassan, Bass
  • Anninga, Jakob
  • Bennister, Lindsey
  • Bovée, Judith V. M. G.
  • Brennan, Bernadette
  • Broto, Javier Martín
  • Brugières, Laurence
  • Cleton-Jansen, Anne-Marie
  • Copland, Christopher
  • Dutour, Aurélie
  • Fagioli, Franca
  • Ferrari, Stefano
  • Fiocco, Marta
  • Fleuren, Emmy
  • Gaspar, Nathalie
  • Gelderblom, Hans
  • Gerrand, Craig
  • Gerß, Joachim
  • Gonzato, Ornella
  • van der Graaf, Winette
  • Hecker-Nolting, Stefanie
  • Herrero Martín, David
  • Klco-Brosius, Stephanie
  • Kovar, Heinrich
  • Ladenstein, Ruth
  • Lancia, Carlo
  • LeDeley, Marie-Cecile
  • McCabe, Martin G.
  • Metzler, Markus
  • Myklebost, Ola
  • Nathrath, Michaela
  • Picci, Piero
  • Potratz, Jenny
  • Redini, Françoise
  • Richter, Günther H. S.
  • Reinke, Denise
  • Rutkowski, Piotr
  • Scotlandi, Katia
  • Strauss, Sandra
  • Thomas, David
  • Tirado, Oscar M.
  • Tirode, Franck
  • Vassal, Gilles
  • Bielack, Stefan S.
This report summarizes the results of the 3rd Joint ENCCA-WP7, EuroSarc, EEC, PROVABES, and EURAMOS European Bone Sarcoma Network Meeting, which was held at the Children's Cancer Research Institute in Vienna, Austria on September 24-25, 2015. The joint bone sarcoma network meetings bring together European bone sarcoma researchers to present and discuss current knowledge on bone sarcoma biology, genetics, immunology, as well as results from preclinical investigations and clinical trials, to generate novel hypotheses for collaborative biological and clinical investigations. The ultimate goal is to further improve therapy and outcome in patients with bone sarcomas.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-κB pathway, independently of the fusion oncoprotein

  • Hernández-Muñoz, Inmaculada
  • Figuerola-Bou, Elisabet
  • Sánchez-Molina, Sara
  • Rodríguez, Eva
  • Fernández-Maríño, A. I.
  • Pardo-Pastor, Carlos
  • Bahamonde, María Isabel
  • Fernández-Fernández, J. M.
  • García-Domínguez, D. J.
  • Hontecillas-Prieto, Lourdes
  • Lavarino, Cinzia
  • Carcaboso, Ángel M.
  • Torres, Carmen de
  • Tirado, Óscar M.
  • Álava, Enrique de
  • Mora, Jaume
Ewing sarcoma (ES) is an aggressive tumor defined by EWSR1 gene fusions that behave as an oncogene. Here we demonstrate that RING1B is highly expressed in primary ES tumors, and its expression is independent of the fusion oncogene. RING1B-depleted ES cells display an expression profile enriched in genes functionally involved in hematological development but RING1B depletion does not induce cellular differentiation. In ES cells, RING1B directly binds the SCN8A sodium channel promoter and its depletion results in enhanced Nav1.6 expression and function. The signaling pathway most significantly modulated by RING1B is NF-κB. RING1B depletion results in enhanced p105/p50 expression, which sensitizes ES cells to apoptosis by FGFR/SHP2/STAT3 blockade. Reduced NaV1.6 function protects ES cells from apoptotic cell death by maintaining low NF-κB levels. Our findings identify RING1B as a trait of the cell-of-origin and provide a potential targetable vulnerability., IHM is a Miguel Servet investigator (Instituto de Salud Carlos III, ISCIII). This work was supported by the Xarxa de Bancs de Tumors de Catalunya sponsored by Pla Director d’Oncologia de Catalunya and by grants from ISCIII-FEDER (PS09/00973; RIC RD12/0042/0014, Red HERACLES), Ministerio de Economía y Competitividad (MEC) (SAF2012-31089 and SAF2015-69762-R), FEDER Funds and by the Asociación Española Contra el Cáncer (AECC). E.Á.’s lab is supported by the AECC, MEC-FEDER (RD12/0036/0017, PT13/0010/0056, RTC-2014-2102-1, ISCIII Sara Borrell CD06/00001, PI12/03102, PI14/01466), the European FP7 Projects EuroSARC (FP7-HEALTH-2011-two-stage, Project 278742 EUROSARC), Euroewing (FP7-HEALTH.2013.2.4.1-1, Project 602856), Fundación Memoria de DM Solorzano Barruso, Fundación Cris contra el Cáncer, Pablo Ugarte Foundation, and Fundación M. García Estrada. O.M.T. is funded by ISCIII-FEDER (CES12/021) and the AECC. AMC is funded by the European FP7 projects (FP7/2007-2013) under a Marie Curie International Reintegration Grant (PIRG-08- GA-2010-276998) and ISCIII-FEDER (CP13/00189). The Ewing group at the Developmental Tumor Biology Laboratory, Hospital Sant Joan de Déu, is supported by the AECC and the generous donations from Pablo Ugarte Foundation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets

  • Baldauf, Michaela C.
  • Orth, Martin F.
  • Dallmayer, Marlene
  • Marchetto, Aruna
  • Gerke, Julia S.
  • Rubio, Rebeca Alba
  • Kiran, Merve M.
  • Musa, Julián
  • Knott, Maximilian M. L.
  • Ohmura, Shunya
  • Li, Jing
  • Akpolat, Nusret
  • Akatli, Ayse N.
  • Özen, Özlem
  • Dirksen, Uta
  • Hartmann, Wolfgang
  • Álava, Enrique de
  • Baumhoer, Daniel
  • Sannino, Giuseppina
  • Kirchner, Thomas
  • Grünewald, Thomas G. P.
Ewing sarcoma is an undifferentiated small-round-cell sarcoma. Although molecular detection of pathognomonic EWSR1-ETS fusions such as EWSR1-FLI1 enables definitive diagnosis, substantial confusion can arise if molecular diagnostics are unavailable. Diagnosis based on the conventional immunohistochemical marker CD99 is unreliable due to its abundant expression in morphological mimics. To identify novel diagnostic immunohistochemical markers for Ewing sarcoma, we performed comparative expression analyses in 768 tumors representing 21 entities including Ewing-like sarcomas, which confirmed that CIC-DUX4-, BCOR-CCNB3-, EWSR1-NFATc2-, and EWSR1-ETS-translocated sarcomas are distinct entities, and revealed that ATP1A1, BCL11B, and GLG1 constitute specific markers for Ewing sarcoma. Their high expression was validated by immunohistochemistry and proved to depend on EWSR1-FLI1-binding to highly active proximal super-enhancers. Automated cut-off-finding and combination-testing in a tissue-microarray comprising 174 samples demonstrated that detection of high BCL11B and/or GLG1 expression is sufficient to reach 96% specificity for Ewing sarcoma. While 88% of tested Ewing-like sarcomas displayed strong CD99-immunoreactivity, none displayed combined strong BCL11B- and GLG1-immunoreactivity. Collectively, we show that ATP1A1, BCL11B, and GLG1 are EWSR1-FLI1 targets, of which BCL11B and GLG1 offer a fast, simple, and cost-efficient way to diagnose Ewing sarcoma by immunohistochemistry. These markers may significantly reduce the number of misdiagnosed patients, and thus improve patient care., This work was supported by the Kind-Philipp-Foundation (to J.M., M.C.B., M.F.O., M.D., A.M, and G.S.), the ‘Deutsche Stiftung für Junge Erwachsene mit Krebs’ (to M.D.), the German National Academic Foundation (to M.C.B. and M.M.L.K.), the ‘Verein zur Förderung von Wissenschaft und Forschung an der Medizinischen Fakultät der LMU München’ (WiFoMed; to T.G.P.G.), the Daimler and Benz Foundation in cooperation with the Reinhard Frank Foundation (to T.G.P.G.), the Friedrich-Baur-Stiftung (to T.G.P.G.) by LMU Munich’s Institutional Strategy LMUexcellent within the framework of the German Excellence Initiative (to T.G.P.G.), the ‘Mehr LEBEN für krebskranke Kinder - Bettina-Bräu-Stiftung’ (to T.G.P.G.), the Fritz-Thyssen Foundation (FTF-40.15.0.030MN, to T.G.P.G. and G.S.), the Wilhelm-Sander-Foundation (2016.167.1 to T.G.P.G.), and the German Cancer Aid (DKH-111886 and DKH-70112257 to T.G.P.G.; DKH-108128 to U.D.), EU FP7 and TRANSCAN EraNet - PROVABES [01KT1310], EU-FP7 EEC [602856-2] to U.D., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma

  • Sheffield, Nathan C.
  • Pierron, Gaelle
  • Klughammer, Johanna
  • Datlinger, Paul
  • Schönegger, Andreas
  • Schuster, Michael
  • Hadler, Johanna
  • Surdez, Didier
  • Guillemot, Delphine
  • Lapouble, Eve
  • Freneaux, Paul
  • Champigneulle, Jacqueline
  • Bouvier, Raymonde
  • Walder, Diana
  • Ambros, Ingeborg M.
  • Hutter, Caroline
  • Sorz, Eva
  • Amaral, Ana Teresa
  • Álava, Enrique de
  • Schallmoser, Katharina
  • Strunk, Dirk
  • Rinner, Beate
  • Liegl-Atzwanger, Bernadette
  • Huppertz, Berthold
  • Leithner, Andreas
  • Pinieux, Gonzague de
  • Terrier, Philippe
  • Laurence, Valérie
  • Michon, Jean
  • Ladenstein, Ruth
  • Holter, Wolfgang
  • Windhager, Reinhard
  • Dirksen, Uta
  • Ambros, Peter F.
  • Delattre, Olivier
  • Kovar, Heinrich
  • Bock, Christoph
  • Tomazou, Eleni M.
Developmental tumors in children and young adults carry few genetic alterations, yet they have diverse clinical presentation. Focusing on Ewing sarcoma, we sought to establish the prevalence and characteristics of epigenetic heterogeneity in genetically homogeneous cancers. We performed genome-scale DNA methylation sequencing for a large cohort of Ewing sarcoma tumors and analyzed epigenetic heterogeneity on three levels: between cancers, between tumors, and within tumors. We observed consistent DNA hypomethylation at enhancers regulated by the disease-defining EWS-FLI1 fusion protein, thus establishing epigenomic enhancer reprogramming as a ubiquitous and characteristic feature of Ewing sarcoma. DNA methylation differences between tumors identified a continuous disease spectrum underlying Ewing sarcoma, which reflected the strength of an EWS-FLI1 regulatory signature and a continuum between mesenchymal and stem cell signatures. There was substantial epigenetic heterogeneity within tumors, particularly in patients with metastatic disease. In summary, our study provides a comprehensive assessment of epigenetic heterogeneity in Ewing sarcoma and thereby highlights the importance of considering nongenetic aspects of tumor heterogeneity in the context of cancer biology and personalized medicine., The following associations supported this work: Courir pour Mathieu, Dans les pas du Géant, Olivier Chape, Les Bagouzamanon, Enfants et Santé, and les Amis de Claire. The study was performed in the context of the following European Union consortia: Euro Ewing (grant agreement no. 602856), BLUEPRINT (grant agreement no. 282510), PROVABES (grant agreement no. 01KT1310), ASSET (grant agreement no. 259348), and TECHNOBEAT (grant agreement no. 668724). N.C.S. was supported by a long-term fellowship of the Human Frontier Science Program (LT000211/2014). J.K. was supported by a DOC Fellowship of the Austrian Academy of Sciences. D. Surdez was supported by the Institut Curie-SIRIC (Site de Recherche Intégrée en Cancérologie) program. E.d.A. was supported by Ministry of Economy and Competitiveness of Spain-FEDER grants (CIBERONC, RD12/0036/0017, PI14/01466), María García-Estrada, CRIS contra el Cáncer Foundations, and Pablo Ugarte Association. C.B. was supported by a New Frontiers Group award of the Austrian Academy of Sciences and by a European Research Council (ERC) Starting Grant (European Union's Horizon 2020 research and innovation program; grant 679146). E.M.T. was supported by fellowships of the Austrian Science Fund (FWF, Lise Meitner Fellowship M1448-B13; and Elise Richter Fellowship V506-B28).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Ewing sarcoma

  • Grünewald, Thomas G. P.
  • Cidre-Aranaz, Florencia
  • Surdez, Didier
  • Tomazou, Eleni M.
  • Álava, Enrique de
  • Kovar, Heinrich
  • Sorensen, Poul
  • Delattre, Olivier
  • Dirksen, Uta
Ewing sarcoma is the second most frequent bone tumour of childhood and adolescence that can also arise in soft tissue. Ewing sarcoma is a highly aggressive cancer, with a survival of 70–80% for patients with standard-risk and localized disease and ~30% for those with metastatic disease. Treatment comprises local surgery, radiotherapy and polychemotherapy, which are associated with acute and chronic adverse effects that may compromise quality of life in survivors. Histologically, Ewing sarcomas are composed of small round cells expressing high levels of CD99. Genetically, they are characterized by balanced chromosomal translocations in which a member of the FET gene family is fused with an ETS transcription factor, with the most common fusion being EWSR1–FLI1 (85% of cases). Ewing sarcoma breakpoint region 1 protein (EWSR1)–Friend leukaemia integration 1 transcription factor (FLI1) is a tumour-specific chimeric transcription factor (EWSR1–FLI1) with neomorphic effects that massively rewires the transcriptome. Additionally, EWSR1–FLI1 reprogrammes the epigenome by inducing de novo enhancers at GGAA microsatellites and by altering the state of gene regulatory elements, creating a unique epigenetic signature. Additional mutations at diagnosis are rare and mainly involve STAG2, TP53 and CDKN2A deletions. Emerging studies on the molecular mechanisms of Ewing sarcoma hold promise for improvements in early detection, disease monitoring, lower treatment-related toxicity, overall survival and quality of life., T.G.P.G. is supported by grants from the Wilhelm Sander Foundation (2016.167.1), German Cancer Aid (DKH-111886 and DKH-70112257) and the Deutsche Forschungsgemeinschaft (DFG 391665916). F.C.-A. is supported by a grant from the Barbara and Hubertus Trettner Foundation. E.M.T. is supported by a fellowship from the Austrian Science Fund (FWF; Elise Richter Fellowship V506-B28). E.d.A. is supported by grants from the Spanish Ministry of Economy-FEDER (PI17/00464, CB16/12/00361), the Asociación Pablo Ugarte and the María García-Estrada Foundation. U.D. is supported by grants from the German Cancer Aid (DKH108128 and DKH 70112018); ERA-Net-TRANSCAN (01KT1310), EEC, EU-FP7 602856, Trettner Foundation and Stiftung für krebskranke Kinder in Essen.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours – EURO EWING 2012 Protocol

  • Anderton, Jennifer
  • Moroz, Verónica
  • Marec-Bérard, Perrine
  • Gaspar, Nathalie
  • Laurence, Valérie
  • Martín-Broto, Javier
  • Sastre, Ana
  • Gelderblom, Hans
  • Owens, Cormac
  • Kaiser, Sophie
  • Fernández-Pinto, Melissa
  • Fenwick, Nicola
  • Evans, Abigail
  • Strauss, Sandra
  • Whelan, Jeremy
  • Wheatley, Keith
  • Brennan, Bernadette
[Background] Although there have been multiple randomised trials in newly diagnosed Ewing sarcoma family of tumours (ESFT) and these have been conducted over many years and involved many international cooperative groups, the outcomes for all stages of disease have plateaued. Internationally, the standard treatment of ESFT is not defined, and there is a need to add new agents other than conventional chemotherapy to improve outcomes. This trial will compare two different induction/consolidation chemotherapy regimens: (1) vincristine, ifosfamide, doxorubicin and etoposide (VIDE) induction and vincristine, actinomycin D, ifosfamide or cyclophosphamide, or busulfan and mephalan (VAI/VAC/BuMel) consolidation and (2) vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide (VDC/IE) induction and ifosfamide and etoposide, vincristine and cyclophosphamide, vincristine, actinomycin D and ifosfamide, or busulfan and mephalan (IE/VC/VAI/BuMel) consolidation (randomisation 1, or R1). A second randomisation (R2) will determine whether the addition of zoledronic acid to consolidation chemotherapy, as assigned at R1, is associated with improved clinical outcome., [Methods] EURO EWING 2012 is an international, multicentre, phase III, open-label randomised controlled trial. There are two randomisations: R1 and R2. Patients are randomly assigned at two different time points: at entry to the trial (R1) and following local control therapy (R2). The primary outcome measure is event-free survival. The secondary outcome measures include overall survival, adverse events and toxicity, histological response of the primary tumour, response of the primary tumour, regional lymph nodes or metastases (or both), and achievement of local control at the end of treatment., [Discussion] This study will establish which is the “standard regimen” of chemotherapy, taking into account both clinical outcomes and toxicity. This will form the chemotherapy backbone for future interventional studies where we may want to add new targeted agents. It will also determine the role of zoledronic acid in conjunction with the separate EE2008 trial. Any trial in ESFT needs to take into account the rarity of the tumour and consider that international cooperation is needed to provide answers in a timely manner., [Trial registration] Registered with EudraCT number 2012-002107-17 on 26 February 2012. Registered with ISRCTN number 92192408 on 4 November 2013., This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement n°602856. The NCC in France, CLB, receives additional funding from SFCE and Ligue contre le cancer. The coordinating sponsor (the University of Birmingham, Birmingham, UK) is funded by Cancer Research UK (grant award reference C5952/A14745).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24–25, 2015. Workshop Report

  • Kager, Leo
  • Whelan, Jeremy
  • Dirksen, Uta
  • Hassan, Bass
  • Anninga, Jakob
  • Bennister, Lindsey
  • Bovée, Judith V. M. G.
  • Brennan, Bernadette
  • Broto, Javier Martín
  • Brugières, Laurence
  • Cleton-Jansen, Anne-Marie
  • Copland, Christopher
  • Dutour, Aurélie
  • Fagioli, Franca
  • Ferrari, Stefano
  • Fiocco, Marta
  • Fleuren, Emmy
  • Gaspar, Nathalie
  • Gelderblom, Hans
  • Gerrand, Craig
  • Gerß, Joachim
  • Gonzato, Ornella
  • van der Graaf, Winette
  • Hecker-Nolting, Stefanie
  • Herrero Martín, David
  • Klco-Brosius, Stephanie
  • Kovar, Heinrich
  • Ladenstein, Ruth
  • Lancia, Carlo
  • LeDeley, Marie-Cecile
  • McCabe, Martin G.
  • Metzler, Markus
  • Myklebost, Ola
  • Nathrath, Michaela
  • Picci, Piero
  • Potratz, Jenny
  • Redini, Françoise
  • Richter, Günther H. S.
  • Reinke, Denise
  • Rutkowski, Piotr
  • Scotlandi, Katia
  • Strauss, Sandra
  • Thomas, David
  • Tirado, Oscar M.
  • Tirode, Franck
  • Vassal, Gilles
  • Bielack, Stefan S.
This report summarizes the results of the 3rd Joint ENCCA-WP7, EuroSarc, EEC, PROVABES, and EURAMOS European Bone Sarcoma Network Meeting, which was held at the Children's Cancer Research Institute in Vienna, Austria on September 24-25, 2015. The joint bone sarcoma network meetings bring together European bone sarcoma researchers to present and discuss current knowledge on bone sarcoma biology, genetics, immunology, as well as results from preclinical investigations and clinical trials, to generate novel hypotheses for collaborative biological and clinical investigations. The ultimate goal is to further improve therapy and outcome in patients with bone sarcomas.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-κB pathway, independently of the fusion oncoprotein.

  • Hernández-Muñoz, Inmaculada
  • Figuerola, Elisabeth
  • Sánchez-Molina, Sara
  • Rodríguez García, Eva
  • Fernández Mariño, Ana Isabel, 1984-
  • Pardo-Pastor, Carlos
  • Bahamonde Santos, María Isabel, 1972-
  • Fernández-Fernández, José Manuel, 1967-
  • García-Domínguez, Daniel J.
  • Hontecillas-Prieto, Lourdes
  • Lavarino, Cinzia
  • Carcaboso, Angel M.
  • Torres, Carmen de
  • Tirado, Oscar M.
  • Alava, Enrique de
  • Mora, Jaume
Ewing sarcoma (ES) is an aggressive tumor defined by EWSR1 gene fusions that behave as an oncogene. Here we demonstrate that RING1B is highly expressed in primary ES tumors, and its expression is independent of the fusion oncogene. RING1B-depleted ES cells display an expression profile enriched in genes functionally involved in hematological development but RING1B depletion does not induce cellular differentiation. In ES cells, RING1B directly binds the SCN8A sodium channel promoter and its depletion results in enhanced Nav1.6 expression and function. The signaling pathway most significantly modulated by RING1B is NF-κB. RING1B depletion results in enhanced p105/p50 expression, which sensitizes ES cells to apoptosis by FGFR/SHP2/STAT3 blockade. Reduced NaV1.6 function protects ES cells from apoptotic cell death by maintaining low NF-κB levels. Our findings identify RING1B as a trait of the cell-of-origin and provide a potential targetable vulnerability., This work was supported by the Xarxa de Bancs de Tumors de Catalunya sponsored by Pla Director d’Oncologia de Catalunya and by grants from ISCIII-FEDER (PS09/00973; RIC RD12/0042/0014, Red HERACLES), Ministerio de Economía y Competitividad (MEC) (SAF2012-31089 and SAF2015-69762-R), FEDER Funds and by the Asociación Española Contra el Cáncer (AECC). E.Á.’s lab is supported by the AECC, MECFEDER (RD12/0036/0017, PT13/0010/0056, RTC-2014- 2102-1, ISCIII Sara Borrell CD06/00001, PI12/03102, PI14/01466), the European FP7 Projects EuroSARC (FP7- HEALTH-2011-two-stage, Project 278742 EUROSARC), Euroewing (FP7-HEALTH.2013.2.4.1-1, Project 602856), Fundación Memoria de DM Solorzano Barruso, Fundación Cris contra el Cáncer, Pablo Ugarte Foundation, and Fundación M. García Estrada. O.M.T. is funded by ISCIIIFEDER (CES12/021) and the AECC. AMC is funded by the European FP7 projects (FP7/2007-2013) under a Marie Curie International Reintegration Grant (PIRG- 08- GA-2010-276998) and ISCIII-FEDER (CP13/00189). The Ewing group at the Developmental Tumor Biology Laboratory, Hospital Sant Joan de Déu, is supported by the AECC and the generous donations from Pablo Ugarte Foundation.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

  • Lázaro García, Conxi
  • GC-HBOC Study Collaborators
  • GEMO Study Collaborators
  • EMBRACE Collaborators
  • HEBON Investigators
  • BCFR Investigators
  • ABCTB Investigators
Genome-wide association studies (GWAS) have identified more than 170 breast cancer susceptibility loci. Here we hypothesize that some risk-associated variants might act in non-breast tissues, specifically adipose tissue and immune cells from blood and spleen. Using expression quantitative trait loci (eQTL) reported in these tissues, we identify 26 previously unreported, likely target genes of overall breast cancer risk variants, and 17 for estrogen receptor (ER)-negative breast cancer, several with a known immune function. We determine the directional effect of gene expression on disease risk measured based on single and multiple eQTL. In addition, using a gene-based test of association that considers eQTL from multiple tissues, we identify seven (and four) regions with variants associated with overall (and ER-negative) breast cancer risk, which were not reported in previous GWAS. Further investigation of the function of the implicated genes in breast and immune cells may provide insights into the etiology of breast cancer.